Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DTacP Vaccine in Healthy Infants
NCT05091619Phase 3Active, not recruiting
- Sponsor
- China National Biotec Group
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of diphtheria + tetanus + acellular pertussis vaccine in pertussis, diphtheria, Tetanus, sponsored by China National Biotec Group. Started Oct 2021; status: active, not recruiting.
02
Drugs
diphtheria + tetanus + acellular pertussis vaccine
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on NCT05091619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091619.